2019 Volume 33 Issue 2 Pages 212-220
“Japanese Pediatric Guideline for the Treatment and Management of Asthma : 2017” Chapter 8 Management of acute exacerbation was outlined. In this revision, what was previously called acute attack is more emphasized that bronchial asthma is a chronic inflammatory disease of the airways, and it is no longer described as “attack” internationally. It was referred to as “acute exacerbation” .
Also, with the aim of making it easy to manage acute exacerbation, a table was newly created to clarify the determination criteria.
Until now, infant asthma has been described in a separate chapter, but the description is unified to one chapter from JPGL 2017, and the inhalation amount of short acting beta2-agonist (SABA) is 0.3 mL regardless of body weight. A systematic review also suggested that inhaled steroids should not be increased during acute exacerbation and that SABA inhalation is comparable to a motorized nebulizer, even with spacers.
The maximum dose was shown for systemic steroid drug administration, and it was decided that intravenous and oral administration have the same effect and that loose administration is avoided.
